MENU
+Compare
PBE
ETF ticker: NYSE ARCA
AS OF
Apr 23 closing price
Price
$60.24
Change
+$0.52 (+0.87%)
Net Assets
214.39M

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for PBE with price predictions
Apr 22, 2025

PBE's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for PBE moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on PBE as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBE just turned positive on April 21, 2025. Looking at past instances where PBE's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

PBE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PBE entered a downward trend on March 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 17.07B. The market cap for tickers in the group ranges from 548.33M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is CDNA at 548.33M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 2%. For the same ETF, the average monthly price growth was -10%, and the average quarterly price growth was -10%. XNCR experienced the highest price growth at 14%, while MYGN experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 10%. For the same stocks of the ETF, the average monthly volume growth was -53% and the average quarterly volume growth was 63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 57
Price Growth Rating: 63
SMR Rating: 72
Profit Risk Rating: 66
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com